<?xml version="1.0" encoding="UTF-8"?>
<p>The calculation of patient-specific optimal TKI doses requires the knowledge of model parameters 
 <italic>p
  <sub>YX</sub>
 </italic>, 
 <italic>p
  <sub>XY</sub>
 </italic>, 
 <italic>e
  <sub>TKI</sub>
 </italic>, and 
 <italic>p
  <sub>Y</sub>
 </italic>. Whereas 
 <italic>p
  <sub>YX</sub>
 </italic>, 
 <italic>p
  <sub>XY</sub>
 </italic>, and 
 <italic>q</italic>=
 <italic>e
  <sub>TKI</sub>
 </italic>−
 <italic>p
  <sub>Y</sub>
 </italic> can be estimated from time course data, the LSC proliferation rate 
 <italic>pY</italic> is confounded with the individual TKI-effect 
 <italic>e
  <sub>TKI</sub>
 </italic> and cannot be deduced directly. Therefore, we propose to estimate 
 <italic>p
  <sub>Y</sub>
 </italic> by observing the transient increase in proliferating LSCs occurring after a first favorable dose reduction. Technically, we suggest a moderate initial reduction to fraction 
 <italic>f</italic> of the standard dose, after the patient’s response under standard dose has been sufficiently quantified in terms of the kinetic parameters (
 <italic>α,β,A,B</italic>) (
 <xref ref-type="fig" rid="f3-1031825">Figure 3A</xref>). Although dose-halving (i.e. 
 <italic>f</italic>=0.5) seems to be safe for this first de-escalation (see below), the proposed approach is valid for any reasonable reduction. After a transient increase in the 
 <italic>BCR-ABL1</italic> levels, a new intercept 
 <italic>B</italic>′ can be observed approximately 18 months after the dose reduction (
 <xref ref-type="fig" rid="f3-1031825">Figure 3B</xref>). Based on the difference of intercepts 
 <italic>B</italic> and 
 <italic>B</italic>′, and the reduction fraction 
 <italic>f</italic>, the proliferation rate 
 <italic>p
  <sub>Y</sub>
 </italic> can be estimated (
 <italic>Online Supplementary Text S9</italic>) by 
 <disp-formula id="fd6-1031825">
  <math id="mm9">
   <mrow>
    <msub>
     <mi>p</mi>
     <mi>Y</mi>
    </msub>
    <mo>=</mo>
    <mrow>
     <mo>|</mo>
     <mi>α</mi>
     <mo>|</mo>
    </mrow>
    <mfrac>
     <mi>B</mi>
     <mrow>
      <mn>1</mn>
      <mo>−</mo>
      <mi>f</mi>
     </mrow>
    </mfrac>
    <mrow>
     <mo>(</mo>
     <mrow>
      <mfrac>
       <mi>f</mi>
       <mi>B</mi>
      </mfrac>
      <mo>−</mo>
      <mfrac>
       <mn>1</mn>
       <mrow>
        <mi>B</mi>
        <mo>′</mo>
       </mrow>
      </mfrac>
     </mrow>
     <mo>)</mo>
    </mrow>
   </mrow>
  </math>
  <label>(E6)</label>
 </disp-formula>and the individual optimal dose reduction fraction 
 <italic>f
  <sub>OPT</sub>
 </italic> can be calculated using 
 <xref ref-type="disp-formula" rid="fd5-1031825">equation (E5)</xref>. This dose is predicted to retain the original long-term treatment efficiency (
 <xref ref-type="fig" rid="f3-1031825">Figure 3C and D</xref>).
</p>
